Interventions to Increase Leukocyte Testing during Treatment with Dimethyl Fumarate.

ABSTRACT: Dimethyl fumarate (DMF), a treatment for multiple sclerosis, may cause leukopenia and infection. Accordingly, periodic white blood cell (WBC) monitoring is recommended. We sought to evaluate the US Department of Veteran Affairs' safety program which provides facilities with a list of patients prescribed DMF therapy without a documented white blood cell count (WBC). We identified 118 sites with patients treated with DMF from 1 January 2016 through 30 September 2016. Each site was asked if any of seven interventions were used to improve WBC monitoring (academic detailing, provider education without academic detailing, electronic clinical reminders, request for provider action plan, draft orders for WBC monitoring, patient mailings, and patient calls). The survey response rate was 78%. For th

SUBMITTER: Heidenreich PA 

PROVIDER: S-EPMC8507868 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature